Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cullinan Therapeutics Inc shares valued at $647,200 were sold by Savill Corrine on Feb 01 ’24. At $16.18 per share, Savill Corrine sold 40,000 shares. The insider’s holdings dropped to 165,990 shares worth approximately $3.2 million following the completion of this transaction.
Also, Savill Corrine sold 40,000 shares, netting a total of over 563,600 in proceeds. Following the sale of shares at $14.09 each, the insider now holds 165,990 shares.
Before that, Savill Corrine had sold 21,316 shares from its account. In a trade valued at $265,597, the Chief Business Officer traded Cullinan Therapeutics Inc shares for $12.46 each. Upon closing the transaction, the insider’s holdings decreased to 21,316 shares, worth approximately $3.2 million.
As published in their initiating research note from William Blair on April 15, 2024, Cullinan Therapeutics Inc [CGEM] has been an Outperform. Analysts at Wedbush started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid February. As of June 15, 2023, TD Cowen has initiated its “an Outperform” rating for CGEM. Earlier on November 21, 2022, BTIG Research initiated its rating. Their recommendation was “a Buy” for CGEM stock.
Analyzing CGEM Stock Performance
During the last five days, there has been a surge of approximately 6.59%. Over the course of the year, Cullinan Therapeutics Inc shares have jumped approximately 88.91%. Shares of the company reached a 52-week high of $20.62 on 04/16/24 and a 52-week low of $10.00 on 01/11/24. A 50-day SMA is recorded $17.19, while a 200-day SMA reached $12.11. Nevertheless, trading volume fell to 1.29 million shares from 0.97 million shares the previous day.
Support And Resistance Levels for Cullinan Therapeutics Inc (CGEM)
According to the 24-hour chart, there is a support level at 18.51, which, if violated, would cause prices to drop to 17.77. In the upper region, resistance lies at 19.71. The next price resistance is at 20.17. RSI (Relative Strength Index) is 62.66 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.05, which suggests the price will increase in the coming days. Percent R is at 25.28%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
